IP Library Granted Patent US 10,808,043
Granted Patent B2
US 10,808,043 · App. 15/541,921 · Granted Oct 20, 2020

Bispecific antibody or antibody mixture with common light chains

Inventors: Ting Xu (Jiangsu, CN); Tao Xu (Jiangsu, CN); Xiaoxiao Wang (Jiangsu, CN); Qian Li (Jiangsu, CN); Minjie Pang (Jiangsu, CN); Huimin Zhang (Jiangsu, CN); Li Han (Jiangsu, CN); Qingqing Zhang (Jiangsu, CN)
Assignee: Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
C07K16/468A61P35/00C07K14/71C07K16/32C12N15/63G01N33/577A61K39/395A61K2039/505A61K2039/507C07K16/28C07K2317/31C07K2317/515C07K2317/52C07K2317/565C07K2317/73C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,808,043
App. No.
15/541,921
Granted
Oct 20, 2020
Kind
B2
Abstract

The present application provides a bispecific antibody or an antibody mixture with common light chains and a preparation method therefor. the present application also provides a nucleic acid molecule encoding the antibody or the mixture, a recombinant vector and a recombinant cell comprising the nucleic acid molecule, as well as a detection and quantitation method for the antibody or the mixture.

Claims (4)

1. An isolated anti-HER2 bispecific antibody or an antigen binding portion thereof, said bispecific antibody or antigen binding portion thereof comprising two heavy chains and two identical light chains, wherein:

each of said light chains comprises a variable region having an amino acid sequence selected from the group consisting of amino acid positions 1-107 of SEQ ID NO: 2-SEQ ID NO:4 and SEQ ID NO:6,

and one of said two heavy chains comprises a variable region having the amino acid sequence of SEQ ID NO:23; and the other one of said two heavy chains comprises a variable region having the amino acid sequence as set forth in SEQ ID NO: 24.

2. A composition comprising the bispecific antibody or the antigen binding portion thereof of claim 1 , and a pharmaceutically acceptable carrier or excipient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2018
From: SUZHOU ALPHAMAB CO., LTD.
To: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD.
Reel/Frame 046750/0759 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2017
From: XU, TING; XU, TAO; WANG, XIAXIAO; LI, QIAN; PANG, MINJIE; ZHANG, HUIMIN; HAN, LI; ZHANG, QINGQING
To: SUZHOU ALPHAMAB CO., LTD
Reel/Frame 042953/0082 →
Priority Claims (1)
CN 2015 1 0008045 · Jan 8, 2015 · national
Continuity (1)
Related Publication 20190031782A1 · Jan 31, 2019
Cited By (3)
US 12,509,527 US 12,540,194 US 12,703,761